NCT02326155View on ClinicalTrials.gov

To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)

TerminatedOBSERVATIONAL
Enrollment

470

Participants

Timeline

Start Date

December 8, 2014

Primary Completion Date

February 28, 2020

Study Completion Date

February 28, 2020

Conditions
Crohn's DiseaseUlcerative Colitis
Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT02326155 - To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC) | Biotech Hunter | Biotech Hunter